Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Zymeworks's Zanidatamab Zovodotin?
Zanidatamab Zovodotin is a monoclonal antibody conjugated commercialized by Zymeworks, with a leading Phase I program in Adenocarcinoma Of The...